Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 15/20 | 0.71 |
| ▸ | MMP9 | P14780 | 15/20 | 0.71 |
| ▸ | MMP3 | P08254 | 3/20 | 0.60 |
| ▸ | MMP13 | P45452 | 3/20 | 0.60 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.44 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.44 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3108337 | 1.00 | MMP2 (0.71) | MMP2MMP9MMP3MMP13MCOLN2 | |
| SCHEMBL8203977 | 0.91 | MMP2 (0.64) | MMP2MMP9MMP3MMP13MCOLN2 | |
| SCHEMBL3116659 | 0.91 | MMP2 (0.64) | MMP2MMP9MMP3MMP13MCOLN2 | |
| SCHEMBL3109502 | 0.83 | MMP2 (1.00) | MMP2MMP9MMP3MMP13 | |
| SCHEMBL8209543 | 0.83 | MMP2 (1.00) | MMP2MMP9MMP3MMP13 | |
| SCHEMBL8195695 | 0.78 | MMP2 (1.00) | MMP2MMP9MMP3MMP13 | |
| SCHEMBL13036926 | 0.78 | MMP2 (0.78) | MMP2MMP9MMP3MMP13 | |
| SCHEMBL8195631 | 0.78 | MMP2 (1.00) | MMP2MMP9MMP3MMP13 | |
| SCHEMBL13074271 | 0.75 | MMP2 (1.00) | MMP2MMP9MMP3MMP13 | |
| SCHEMBL3607169 | 0.75 | MMP2 (1.00) | MMP2MMP9MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-04 | — | — | US | disclosed |
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-04 | — | — | US | disclosed |
| US-7803793-B2 | Heterocyclic derived metalloprotease inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-28 | — | — | US | disclosed |
| US-7803793-B2 | Heterocyclic derived metalloprotease inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-28 | — | — | US | disclosed |
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008045668-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | MMP2 16/4885MMP9 8/4885MMP3 17/4885 |
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | MMP2 16/4885MMP9 8/4885MMP3 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.